Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHAR359 > Oncology 3 > Flashcards

Oncology 3 Flashcards

(88 cards)

Start Studying
1
Q

What is the role of epidermal growth factor receptors?

A

regulate cell differentiation, proliferation, and survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the four EGFR receptors?

A

HER1
HER2
HER3
HER4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Through which pathway does EGFR act?

A

tyrosine kinase pathways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are growth factors?

A

chemicals produced by the body that control cell growth
-some tell cells what type of cells they should become
-some make cells grow and divide into new cells
-some tell cells to stop growing or to die

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do growth factors work?

A

by binding to receptors on the cell surface
-this sends a signal to the inside of the cell, which sets off a chain of complicated chemical reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the difference between mAbs and TKIs in terms of where they act at the cell?

A

mAbs work extracellularly
TKIs work intracellularly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

In which cancer is EGFR gene commonly overexpressed or mutated?

A

non-small cell lung cancer
-EGFR mutation present in 10-15% of patients (30-40% of Asian pts)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the role of the following growth factors?
-EGF
-VEGF
-PDGF
-FGF

A

epidermal growth factor (EGF):
-controls cell growth
vascular endothelial growth factor (VEGF):
-controls blood vessel development
platelet derived endothelial growth factor (PDGF):
-controls blood vessel development and cell growth
fibroblast growth factor (FGF):
-controls cell growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are cancer growth blockers?

A

a targeted drug that blocks the growth factors that trigger cancer cells to divide and grow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the types of cancer growth blockers?

A

tyrosine kinase inhibitors
proteasome inhibitors
mTOR inhibitors
Hedgehog pathway blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Provide the correct naming for small molecule drugs.

A

-tinib: TKI
-zomib: proteasome inhibitor
-ciclib: CDK inhibitor
-parib: PARP inhibitor
-irolimus: mTOR inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which TKI was the pioneer?

A

imatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the MOA of TKIs?

A

block chemical messengers (enzymes) called tyrosine kinases
-TKs help to send growth signals in cells, so blocking them stops the cell growing and dividing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is a multi-TKI?

A

TKIs that block more than one type of TK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which TKI does not end in “-tinib”?

A

pazopanib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are examples of multi-TKIs?

A

sorafenib
sunitinib
vandetinib
cabozantinib
lenvantinib
pazopanib
regorafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

True or false: the therapeutic use and toxicities of multi-TKIs are the same

A

false
some targets may overlap but therapeutic use and toxicities are different

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the TKI-EGFR inhibitors for NSCLC?

A

erlotinib
gefitinib
afatinib
osimertinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Differentiate the TKI-EGFR inhibitors based on target.

A

erlotinib:
-EGFR TK cytosolic domain
gefitinib:
-EGFR TK cytosolic domain
afatinib:
-EGFR, HER2, HER4, HER3 transphorylation
osimertinib:
-EGFR, HER2, HER3, ACK1, BLK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Differentiate the TKI-EGFR inhibitors based on drug interactions.

A

erlotinib: CYP 3A4, PPI
gefitinib: CYP 3A4, 2D6
afatinib: P-gp
osimertinib: CYP 3A4, QT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Differentiate the TKI-EGFR inhibitors based on adverse effects.

A

erlotinib and gefitinib:
-rash, sun sensitivity, diarrhea
afatinib:
-rash, diarrhea, paronychia
osimertinib: milder ADR
-cardiomyopathy, vision disturbance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Which TKI-EGFR inhibitor is used for the T790M mutation?

A

osimertinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Which cancer are ALK fusion genes sometimes present in?

A

~5% of patients with NSCLC
-more common in young pts who are non-smokers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the MOA of ALK inhibitors?

A

block an enzyme called anaplastic lymphoma kinase
-only work in cancer cells that have an overactive version of ALK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Which cancer are ALK inhibitors often used in?
some people with advanced NSCLC
26
What are examples of TKI-ALK inhibitors?
alectinib brigatinib ceritinib crizotinib lorlatinib
27
Which TKI-ALK is often first line for advanced NSCLC (ALK+)?
alectinib
28
What is a PK advantage of alectinib?
better CNS penetration if brain metastases
29
What are the side effects of ALK inhibitors?
most commonly GI toxicities (NVD) some lab abnormalities -elevated AST and ALT less common: pneumonitis
30
What are examples of TKIs that target HER2?
lapatinib neratinib pyrotinib tucatinib
31
Which blood vessel related process is unregulated in many tumors?
angiogenesis -tumor growth, invasion, and metastasis
32
What is the master regulator of angiogenesis?
VEGF
33
What has emerged as potent anti-tumor weapons against multiple solid tumors?
VEGFR-associated multi-targeted TKIs
34
What is the use of axitinib?
metastatic renal cell cancer
35
What are the adverse effects of axitinib?
hypertension bleeding impaired wound healing
36
What are the drug interactions of axitinib?
substrate of CYP 3A4 acid blockers
37
What are the targets of sunitinib and pazopanib?
VEGF PDGFR c-KIT
38
What are the uses of sunitinib and pazopanib?
both: metastatic renal cell carcinoma sunitinib: -GI stromal tumor -pancreatic neuroendocrine tumor
39
What are the adverse effects of sunitinib and pazopanib?
nausea, diarrhea hand foot skin reaction (palmar erythrodysesthesia) discoloration of nails or hair hypothyroidism HTN, QT prolongation, decreased LVEF bleeding
40
What are the drug interactions of sunitinib and pazopanib?
substrates of CYP 3A4
41
What are the uses of sorafenib and regorafenib?
sorafenib: -metastatic hepatocellular carcinoma regorafenib: -GIST -hepatocellular carcinoma
42
What are the adverse effects of sorafenib and regorafenib?
GI (less severe than sunitinib) HFSR (more common than sunitinib) severe rash, mild skin discolouration hypertension bleeding metabolic and electrolyte abnormalities cardiotoxicity & QT
43
What are the drug interactions of sorafenib and regorafenib?
substrates of 3A4 sorafenib inhibits 2B6, 2C8
44
What are the indications for lenvatinib?
thyroid cancer hepatocellular carcinoma renal cell carcinoma endometrial cancer -advanced endometrial with pembrolizumab
45
What do most people with CML have?
abnormal chromosome called the Philadelphia chromosome
46
What causes the development of the Philadelphia chromosome?
ABL1 gene on chromosome 9 breaks off and sticks to a gene called the BCR gene on chromosome 22 -produces a new gene called BCR-ABL1, known as a fusion gene
47
What is an example of a BCR-ABL inhibitor?
imatinib
48
What are the targets of imatinib?
BCR-ABL kinase PDGF c-KIT
49
What are the adverse effects of imatinib?
edema hepatotoxicity bone marrow suppression
50
What are the drug interactions of imatinib?
CYP 3A4
51
What are around half of melanomas caused by?
a mutation in a gene called BRAF
52
What is the issue with BRAF inhibitors?
they quickly develop resistance
53
What is the MOA of BRAF inhibitors?
they target the faulty BRAF gene -blocking the BRAF protein to slow or stop the growth of the cancer
54
What are examples of BRAF inhibitors?
vemurafenib dabrafenib encorafenib
55
What are BRAF inhibitors used in combination with for melanomas?
MEK inhibitors
56
What are the adverse effects of BRAF inhibitors?
cutaneous toxicities -maculopapular rash (common) -phototoxic reactions (wear sunscreen) -squamoproliferative lesions -alopecia
57
Describe the interplay of BRAF and MEK.
the BRAF protein can affect other proteins, such as MEK, which makes cancer cells divide and grow in an uncontrolled way
58
What is the MOA of MEK inhibitors?
they block the MEK protein, which slows down the growth of cancer cells
59
What are examples of MEK inhibitors used for melanoma?
trametinib cobimetinib binimetinib
60
What are the usual BRAF and MEK inhibitor combinations for melanoma?
dabrafenib with trametinib vemurafenib with cobimetinib encorafenib with binimetinib
61
Why are BRAF inhibitors and MEK inhibitors combined in melanoma?
synergistic and delays onset of drug resistance -tolerability is also improved
62
What are the adverse effects of MEK inhibitors?
fewer cutaneous squamous cell carcinomas acneiform rash cardiotoxicities ocular toxicity
63
What are the drug interactions of MEK inhibitors?
trametinib: none significant cobimetinib: substrate of 3A4
64
What are proteasomes?
tiny, barrel shaped structures found in all cells -they help break down proteins the cell doesnt need into smaller parts -the cell can then use them to make new proteins that it does need
65
What is bortezomib?
a proteasome inhibitor used to treat multiple myeloma
66
What is the MOA of proteasome inhibitors?
cause a buildup of unwanted proteins in the cell, which makes the cancer cells die
67
What are examples of proteasome inhibitors?
bortezomib (sc) carfilzomib (IV) ixazomib (po)
68
What are proteasome inhibitors used for?
multiple myeloma
69
What are the adverse effects of proteasome inhibitors?
neutropenia thrombocytopenia peripheral neuropathy diarrhea reactivation of Hep B or Herpes zoster
70
What is recommend to combat the increased risk of herpes zoster or herpes simplex reactivation with proteasome inhibitors?
antiviral prophylaxis -valacyclovir for seropositive pts
71
How can bortezomib-induced peripheral neuropathy be curtailed?
adjustments in route (SC rather than IV) and scheduling (weekly vs more frequent) -less common and less severe with carfilzoimb and ixazomib
72
What can repair DNA strand breaks?
single-stranded breaks: PARP double-stranded breaks: BRCA1, BRCA2
73
What happens if PARP enzymes are inhibited?
cancer cells lose one of the major mechanisms to repair single-stranded DNA breaks, which decreases their viability
74
What are cancer cells with mutated BRCA genes less able to do?
repair dsDNA breaks, thus more likely to die -because ssDNA breaks left unrepaired by the PARP inhibition will turn into dsDNA breaks during DNA replication -inhibitors of PARP can stop the growth of cancer, particularly cancers that have mutated BRCA genes
75
Which cancers are PARP inhibitors used for?
gynecological breast prostate *specifically cancers with BRCA mutation*
76
What are the ovarian cancer indications for PARP inhibitors?
niraparib: -advanced or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and who are in response to platinum-based chemo olaparib: -recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA-mutation and who are in response to platinum-based chemo
77
What are the breast cancer indications for PARP inhibitors?
olaparib: -early stage, high risk BRCA mutated, HER2 negative as adjuvant tx, continues for 1yr
78
What are the prostate cancer indications for PARP inhibitors?
olaparib: -metastatic castration resistant prostate cancer with BRCA or ATM mutations niraparib/abiraterone: -combination production for metastatic castration resistant prostate cancer with BRCA mutation with prednisone
79
How is progression through different phases of the cell cycle controlled?
by a group of proteins called cyclins
80
What occurs when there is dysregulation in CDK4 and CDK6?
allows cancer cells, despite their genetic damage, to progress through the G1 checkpoint to the S phase of the cell cycle
81
What are CDK4/6 inhibitors used for?
adjuvant and metastatic breast cancer
82
Which cancer is CDK often overexpressed in?
breast
83
Which therapies are CDK inhibitors synergistic with?
anti-estrogen therapies
84
What are examples of CDK4/6 inhibitors?
abemaciclib -continuous palbociclib -3 wks on 1 wk off ribociclib -3 wks on 1 wk off
85
What are the adverse effects of abemaciclib?
neutropenia (23%, less) diarrhea (85%, the downside) increased ALT/AST alopecia increased creatinine VTE/PE pneumonitis
86
What are the adverse effects of palbociclib?
neutropenia (55%) diarrhea (26%) alopecia VTE/PE pneumonitis
87
What are the adverse effects of ribociclib?
neutropenia (61%) diarrhea (35%) increased ALT/AST alopecia VTE/PE QT prolongation pneumonitis
88
What are the drug interactions of the CDK inhibitors?
abemaciclib: -3A4 substrate, P-gp substrate palbociclib: -3A4 substrate, weak inhibitor ribociclib: -3A4 substrate, moderate inhibitor, QT

PHAR359 (28 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions